Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

1. Cannabis Use During Pregnancy and Lactation: A Practice Resources for Health Care Providers

) was enacted, establishing a framework for the possession, distribution, sale and production of cannabis in Canada. (5) Cannabis is defined in the Act to include marijuana, hashish, hash oil or any other preparation of the cannabis plant. (5) In 2016, 16.9% of Canadian women between the ages of 15-44 reported past year use of cannabis which was an increase from the self reported 12.6% in 2015. (6) In British Columbia (BC), approximately 3.5% of pregnant women and individuals reported cannabis use (...) -on-Obstetric-Practice/Marijuana- Use-During-Pregnancy-and-Lactation?IsMobileSet=false n Midwives Association of British Columbia. Is it safe to use weed during pregnancy? https://www.bcmidwives.com/cgi/page.cgi/_zine.html/News_Announcements/Is_it_ safe_to_use_weed_during_pregnancy_ n Canadian Association of Midwives. Cannabis Use during Pregnancy. https:// canadianmidwives.org/2018/10/15/cannabis-use-during-pregnancy/ n Champlain Maternal Newborn Regional Program (CMNRP). Cannabis and Lactation Discussion

2020 British Columbia Perinatal Health Program

2. Cannabis and Your Medications

Cannabis and Your Medications Cannabis can interact with your medications and affect your health. For more information, talk to your healthcare provider. Medications that can interact with cannabis PAIN medications HEART medications and BLOOD THINNERS SLEEPING PILLS ANTI-SEIZURE medications ANTI- DEPRESSANTS and ANTI-ANXIETY medications ANTIBIOTIC and ANTIFUNGAL medications ADHD medications Drugs to treat HIV/AIDS ALLERGY medications COLD and FLU medications HEARTBURN medications Learn about (...) the health effects of cannabis at ccsa.ca/cannabis and canada.ca/cannabis Cannabis and Your Medication © Canadian Centre on Substance Use and Addiction 2020

2020 Canadian Centre on Substance Abuse

3. Cannabis and Other Substances

Cannabis and Other Substances Cannabis and Other Substances Learn about the health effects of cannabis at ccsa.ca/cannabis and canada.ca/cannabis Using cannabis with alcohol can increase your risk of over-intoxication and impair your ability to drive safely. Smoking cannabis with tobacco increases exposure to chemicals that can further your risk of developing lung and heart disease. Using cannabis with drugs (e.g., MDMA, cocaine, opioids, heroin, etc.) can lead to interactions that can (...) be dangerous to your health. © Canadian Centre on Substance Use and Addiction 2020 Cannabis used with other substances can lead to negative impacts on your health. Using cannabis with tobacco can increase the risk for dependence on these substances more than smoking either one alone. If you choose to use cannabis, be aware of the risks of mixing with other substances. TOBACCO OTHER ALCOHOL

2020 Canadian Centre on Substance Abuse

4. Position Statement on the medicinal use of Cannabinoids in Pain Medicine

Position Statement on the medicinal use of Cannabinoids in Pain Medicine Faculty Position Statement on the medicinal use of Cannabinoids in Pain Medicine Update following the publication of NICE Guidance NG144 (11 November 2019) This statement is focused on the issues relating to cannabis derived medicinal products in relation to Pain Medicine. It does not comment on other areas of medical practice or recreational use, which lie outside our remit. The issue of cannabis, its extracts (...) , Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD012182. DOI: 10.1002 /14651858.CD012182.pub2 3. Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, et al. Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. PAIN. 2018;159(10):1932-54. 4. National Academies

2020 Faculty of Pain Medicine

5. Herbal cannabis and pharmaceutical cannabinoid treatment following motor vehicle accidents: A state of the science review

recommendation) — Nabilone is off-label for pain and has limited evidence of benefit. However, it is less expensive than nabiximols and dosing is more consistent than for smoked cannabis — Nabiximols is expensive and, in some provinces, only available through specialist prescribing or special authorization. However, nabiximols has better evidence than nabilone does -If considering medical cannabinoids, we recommend against medical marijuana (particularly smoked) as the initial product (strong recommendation (...) Herbal cannabis and pharmaceutical cannabinoid treatment following motor vehicle accidents: A state of the science review Herbal cannabis and pharmaceutical cannabinoid treatment following motor vehicle accidents: A state of the science review Final Report Carolyn J Green, PhD Ken L Bassett, MD, PhD Therapeutics Initiative University of British Columbia October 2018 Table of Contents 1.0 Developing a funding policy framework for ICBC insurance claims 1 1.1 Scientific medical knowledge

2020 Therapeutics Letter

6. Cannabis-based medicinal products

technology appraisal guidance on cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Products covered by the guideline include: cannabis-based products for medicinal use as set out by the UK Government in the 2018 Regulations the licensed products delta-9-tetrahydrocannibinol combined with cannabidiol (Sativex) and nabilone plant-derived cannabinoids such as pure cannabidiol (CBD) synthetic compounds which are identical in structure to naturally (...) occurring cannabinoids such as delta-9-tetrahydrocannabinol (THC), for example, dronabinol. Who is it for? Who is it for? Healthcare professionals People taking cannabis-based medicinal products, their families and carers Cannabis-based medicinal products (NG144) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 27Recommendations Recommendations People have the right to be involved in discussions and make informed

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Barriers to accessing cannabis-based products for medicinal use on NHS prescription

Barriers to accessing cannabis-based products for medicinal use on NHS prescription NHS England » Barriers to accessing cannabis-based products for medicinal use on NHS prescription Search Search Menu Barriers to accessing cannabis-based products for medicinal use on NHS prescription Document first published: 8 August 2019 Page updated: 8 August 2019 Topic: Publication type: This document provides information on the findings and recommendations following NHS England and NHS Improvement’s review (...) of the barriers to prescribing of cannabis-based products for medicinal use. Document PDF 290 KB 20 pages

2019 NHS England

8. Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines

of cannabinoids in the treatment of dementia. Sources of uncertainty included the low quality of evidence in the primary studies of the systematic review3 and the fact that the uncontrolled before-and-after study10 was a nonrandomized pilot study in 10 dementia patients that reported descriptive outcomes without statistical analysis. No relevant evidence-based clinical guidelines regarding the use of medical cannabis for treating dementia were identified. Files Rapid Response Summary with Critical Appraisal (...) Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines Last updated: July 17, 2019 Project Number: RC1152-000 Product

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical Effectiveness and Guidelines

Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical Effectiveness and Guidelines Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical Effectiveness and Guidelines Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical Effectiveness and Guidelines Last updated: July 24, 2019 Project Number: RC1153 (...) -000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of medical cannabis for the treatment of chronic pain? What are the evidence-based guidelines associated with the use of medical cannabis for the treatment of chronic pain? Key Message Based on four overviews (with overlapping systematic reviews), and one systematic review of guidelines,8 there is some suggestion of benefit with cannabis-based medicines

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Cannabis use in the Immunocompromised increasing rates of Pulmonary Aspergillus

Cannabis use in the Immunocompromised increasing rates of Pulmonary Aspergillus "Cannabis use in the Immunocompromised increasing rates of Pulmonary As" by Molly Burns < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Cannabis use is an emerging remedy among immunocompromised patients. The lack of regulation surrounding marijuana treatment creates a culture of concern (...) for patients. The act of inhalation further inhibits these patients’ immune response to pathogens. Additionally, marijuana cultures are heavily contaminated with Aspergillus fungus. This review assesses the evidence for a correlation between cannabis use in the immunocompromised and cases of pulmonary aspergillus. Recommended Citation Burns, Molly, "Cannabis use in the Immunocompromised increasing rates of Pulmonary Aspergillus" (2019). School of Physician Assistant Studies . 676. https

2019 Pacific University EBM Capstone Project

11. Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products

Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products | Canadian Centre on Substance Use and Addiction Search the CCSA website Search Substances and Addiction SPOTLIGHT Health and Public Safety SPOTLIGHT People and Communities SPOTLIGHT Data Trends SPOTLIGHT About Us SPOTLIGHT Menu Search the CCSA website Search Substances and Addiction SPOTLIGHT Health (...) and Public Safety SPOTLIGHT People and Communities SPOTLIGHT Data Trends SPOTLIGHT About Us SPOTLIGHT Breadcrumb Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products Share Topic Summary Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products Publication date: 2019 Author: Canadian Centre on Substance Use and Addiction Provides an overview of edible cannabis products, cannabis extracts and topical cannabis products

2019 Canadian Centre on Substance Abuse

12. Cannabis: Inhaling vs Ingesting

Cannabis: Inhaling vs Ingesting Cannabis: Inhaling vs Ingesting INHALING — smoking or vaping — INGESTING — eating or drinking — Cannabis smoke or vapour delivers THC, the chemical that gets you high, into your lungs where it passes directly into your bloodstream and then your brain. Edible cannabis travels first to your stomach then to your liver before getting into your bloodstream and brain. The liver converts THC into a stronger form and this combined with the THC from the original product (...) adds to the intensity of the high. To lower your risk of the harmful effects of cannabis, you need to understand the differences between the two most common ways of consuming it. To learn more visit ccsa.ca/cannabis | canada.ca/cannabis TIPS FOR LOWER-RISK USE START OF EFFECTS PEAK EFFECTS LENGTH OF EFFECTS • Ingesting and vaping are less harmful to your lungs than smoking. • If you are new to edible cannabis or cannabis, start low by consuming an edible cannabis product with no more than 2.5 mg

2019 Canadian Centre on Substance Abuse

13. Understanding the Health Effects of Recreational Cannabis Use: A Focused Practice Question

. The National Academies of Sciences, Engineering and Medicine (2017): The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. 4 This strong-quality review of reviews examined the health consequences of using cannabis or its constituents. It provided recommendations on the most critical research questions to be answered in the short- and long-term, and what is required to address those questions. The report was not intended to be a systematic review (...) Understanding the Health Effects of Recreational Cannabis Use: A Focused Practice Question Understanding the Health Effects of Recreational Cannabis Use A Focused Practice Question Region of Peel – Public Health Chronic Disease and Injury Prevention Division & Family Health Division August 2019 Please use the following citation when referencing this document: Region of Peel – Public Health. Understanding the health effects of recreational cannabis use: A focused practice question. Mississauga

2019 Peel Health Library

14. Know the Health Effects of Cannabis

Know the Health Effects of Cannabis Mental Health Daily or near-daily use of cannabis can contribute to dependence and mental health problems over time. Know the Health Risks of Cannabis Driving Cannabis can impair your motor coordination, judgment and other skills required for safe driving. Respiratory Effects Toxic and carcinogenic chemicals found in tobacco smoke are also found in cannabis smoke, and can affect the lungs and airways. Pregnancy Substances in cannabis are transferred from (...) mother to child and can affect your baby. Not using cannabis if pregnant or breastfeeding is the safest option. Stay Informed ccsa.ca/cannabis canada.ca/cannabis Edible Cannabis Consuming too much THC can lead to over-intoxication, which includes intense anxiety, vomiting and symptoms of psychosis (paranoia). Cannabis Extracts Cannabis extracts with high THC content increase the risk of over- intoxication and addiction.

2019 Canadian Centre on Substance Abuse

15. Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products

cannabinoid pharmacokinetics. Chemistry and Biodiversity, 4(8), 1770–1804. 4. Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42(4), 327–360. 5. Berger, E. (2014). Legal marijuana and pediatric exposure: Pot edibles implicated in spike in child emergency department visits. Annals of Emergency Medicine, 64(4), A19–A21. 6. Potera, C. (2015). Kids and marijuana edibles: A worrisome trend emerges. American Journal of Nursing, 115(9), 15. 7. Alzghari (...) Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products www.ccsa.ca • www.ccdus.ca Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products Edible Cannabis (or Edibles) Edible cannabis (or edibles for short) are products containing cannabinoids that you eat or drink. Cannabinoids are chemical compounds

2019 Canadian Centre on Substance Abuse

16. 7 Things You Need to Know about Edible Cannabis

7 Things You Need to Know about Edible Cannabis www.ccsa.ca • www.ccdus.ca Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 7 Things You Need to Know about Edible Cannabis What Is Edible Cannabis? Edible cannabis products (edibles for short) are products containing cannabinoids that you eat or drink. Cannabinoids are chemical compounds found in cannabis that can affect your mind and body when consumed. THC (tetrahydrocannabinol (...) ) is a cannabinoid that makes an individual euphoric and intoxicated (or high). CBD (cannabidiol) is a non-intoxicating cannabinoid that might have some therapeutic benefit, although more research is needed to confirm its potential medical use. There is a wide range of edible cannabis products. Although some edible cannabis products might look like normal food items, they are not food and are not intended to provide any nutritional value. Edible cannabis products provide an alternative method of cannabis

2019 Canadian Centre on Substance Abuse

17. Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. Full Text available with Trip Pro

Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. Recent evidence suggests that cannabis use during pregnancy is increasing, although population-based data about perinatal outcomes following in utero exposure remain limited.To assess whether there are associations between self-reported prenatal cannabis use and adverse maternal and perinatal outcomes.Population-based retrospective cohort study covering live births and stillbirths among women (...) aged 15 years and older in Ontario, Canada, between April 2012 and December 2017.Self-reported cannabis exposure in pregnancy was ascertained through routine perinatal care.The primary outcome was preterm birth before 37 weeks' gestation. Indicators were defined for birth occurring at 34 to 36 6/7 weeks' gestation (late preterm), 32 to 33 6/7 weeks' gestation, 28 to 31 6/7 weeks' gestation, and less than 28 weeks' gestation (very preterm birth). Ten secondary outcomes were examined including small

2019 JAMA

18. Edibles, Extracts and Topicals: A Primer on the New Cannabis Products

. Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry and Biodiversity, 4(8), 1770–1804. 4. Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42(4), 327–360. 5. Berger, E. (2014). Legal marijuana and pediatric exposure: Pot edibles implicated in spike in child emergency department visits. Annals of Emergency Medicine, 64(4), A19–A21. 6. Potera, C. (2015). Kids and marijuana edibles: A worrisome trend emerges. American Journal (...) Edibles, Extracts and Topicals: A Primer on the New Cannabis Products www.ccsa.ca • www.ccdus.ca Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products Edible Cannabis (or Edibles) Edible cannabis (or edibles for short) are products containing cannabinoids that you eat or drink. Cannabinoids are chemical compounds found in cannabis

2019 Canadian Centre on Substance Abuse

19. Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning

current understanding of this issue. Other reports in this series address the link between chronic cannabis use and mental health, the effects of maternal cannabis use during pregnancy, cannabis use and driving, the respiratory effects of cannabis use and the medical use of cannabis and cannabinoids. This series is intended for a broad audience, including health professionals, policy makers and researchers. 1 62 Background Cannabis, also referred to as marijuana, is the second most widely used (...) that are often used interchangeably with regular use include frequent use, chronic use and long-term use. Heavy use, by contrast, typically refers to daily or more frequent use, and can be a sign of dependence and cannabis use disorder. Cannabis is a greenish or brownish material consisting of the dried flowering, fruiting tops and leaves of the cannabis plant, Cannabis sativa. Hashish or cannabis resin is the dried brown or black resinous secretion of the flowering tops of the cannabis plant. Cannabis can

2019 Canadian Centre on Substance Abuse

20. Pharmacotherapy for the Treatment of Cannabis Use Disorder

of pharmacotherapies for CUD, and many of the existing studies are hampered by poor methodological quality or reporting. There is moderate strength evidence that antidepressants do not reduce cannabis use or improve treatment retention, and may be associated with lower rates of abstinence. There also is low to moderate strength of evidence that buspirone, and N-acetylcysteine do not improve outcomes. Although investigators found that cannabinoids do not improve retention, increase rates of abstinence, or reduce (...) (i.e., divalproex, lithium), atomoxetine, cannabinoids, anticonvulsants (i.e., topiramate, gabapentin), N-acetylcysteine, arepitant, and oxytocin. Antidepressants were the most widely studied drug class. Given increasing access to and use of cannabis in the general population (including Veterans), along with the high prevalence of cannabis use disorder among current cannabis users, there is an urgent need for more research to identify effective pharmacologic treatments. Implications Findings

2019 Veterans Affairs - R&D